Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

OBJECTIVES: To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). METHODS: In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: van der Heijde, Désirée, Deodhar, Atul, Wei, James C, Drescher, Edit, Fleishaker, Dona, Hendrikx, Thijs, Li, David, Menon, Sujatha, Kanik, Keith S
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Clinical and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5738601/
https://ncbi.nlm.nih.gov/pubmed/28130206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-210322
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados